Phase 1 Randomized Double-Blind Placebo-Controlled Trial of LIB-01 for Safety and Pharmacokinetics in Erectile Dysfunction

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of LIB-01 in healthy participants. This is a Phase 1, randomized, double-blind, parallel, and placebo-controlled trial designed to assess the initial safety profile and pharmacokinetic parameters of LIB-01, which is relevant for understanding its potential therapeutic application in conditions such as **erectile dysfunction**. The study aims to determine the appropriate dosage range and identify any adverse effects, which are critical steps in the development of new pharmacological treatments.

The clinical trial focuses on **erectile dysfunction** and involves a study population exclusively composed of male participants. The age range of the participants falls within categories 3 and 4, which typically correspond to adult and middle-aged groups. The trial does not include a vulnerable population, and the selection criteria for participants have not been specified by the sponsor. Additionally, the sponsor has not provided information regarding the total number of participants involved in the study. Lifestyle considerations such as diet, physical activity, or habits have not been detailed in the available data.

The clinical trial is a **Phase 1**, randomized, double-blind, parallel, and placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of LIB-01 in healthy participants. The trial specifically targets **erectile dysfunction** and is structured to include both single and multiple ascending dose assessments. The estimated recruitment start date is August 22, 2023, with an anticipated completion date of March 31, 2024, indicating an overall trial duration of approximately seven months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion in the trial. Following successful screening, participants will be randomized into either the treatment or placebo group, maintaining the double-blind nature of the study to ensure unbiased results.

Throughout the trial, participants will attend multiple follow-up visits, which are critical for monitoring safety and collecting pharmacokinetic data. These visits will involve routine assessments, including physical examinations, laboratory tests, and the collection of any adverse event data. The sequence and frequency of these visits are designed to ensure participant safety and the integrity of the data collected.

The end-of-study visit marks the conclusion of a participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the participant's response to the treatment. The expected length of participant involvement will vary depending on the dosing schedule but will generally align with the overall trial timeline.

Participants may be subject to early termination from the study under certain conditions, such as the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent. These conditions are in place to prioritize participant safety and maintain the scientific validity of the trial.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is August 22, 2023, with an anticipated end date of March 31, 2024. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to gather data on the investigational product's effects. The schedule for measuring and collecting efficacy data is not specified, but it generally aligns with the trial's timeline and objectives. The analysis of collected data will be conducted in accordance with standard clinical trial protocols to ensure accurate and reliable results.